Beta-blockers in the treatment of heart failure CIBIS III Trial

Maciej Banach; Marcin Barylski

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Abstracting and indexing Contact Instructions for authors

10/2005
vol. 8

Send email

Copy url:

abstract:

Beta-blockers in the treatment of heart failure CIBIS III Trial

Maciej Banach

,

Marcin Barylski

Przew Lek 2005; 10; 86-86-93

Online publish date: 2005/12/22

View full text Get citation

Heart failure is a very important problem in health care system. In Europe there are almost 10 millions and in Poland half a million patients with left ventricular dysfunction. Heart failure is a clinical disorder characterized by insufficient perfusion of peripheral tissues and fluid retention. Improvement of heart contractility is one of the major therapeutic aims among patients with left ventricular dysfunction. The exact knowledge of methods of heart assistance is indispensable in practice both cardiologist, cardiac surgeons and general practitioners. Beta-blockers are the most important medicines used in the treatment of heart failure. Each new clinical trial informs about the additional benefits resulting of their application. The similarly effect we have already observed during recent presentation of CIBIS III.

keywords:

Beta-blockers in the treatment of heart failure CIBIS III Trial

Maciej Banach , Marcin Barylski

beta-blockers, CIBIS III Trial, heart failure

Maciej Banach

,

Marcin Barylski